scholarly journals Musculoskeletal Findings, Connective and Soft Tissue Findings Time Point Reference

2020 ◽  
Author(s):  
Keyword(s):  
Soft Tissue ◽  
Connective And Soft Tissue ◽  
Time Point

Connective and Soft Tissue Finding

2020 ◽  
Author(s):  
Keyword(s):  
Soft Tissue ◽  
Connective And Soft Tissue

Connective and Soft Tissue Cell

2020 ◽  
Author(s):  
Keyword(s):  
Soft Tissue ◽  
Tissue Cell ◽  
Connective And Soft Tissue

Connective and Soft Tissue Disorder

2020 ◽  
Author(s):  
Keyword(s):  
Soft Tissue ◽  
Connective And Soft Tissue

scholarly journals Connective and Soft Tissue Injury

2020 ◽  
Author(s):  
Keyword(s):  
Soft Tissue ◽  
Tissue Injury ◽  
Soft Tissue Injury ◽  
Connective And Soft Tissue

Trends of cancer mortality in Europe, 1955–1989: II, respiratory tract, bone, connective and soft tissue sarcomas, and skin

1992 ◽  
Vol 28 (2-3) ◽  
pp. 514-599 ◽  
Author(s):  
C. La Vecchia ◽  
F. Lucchini ◽  
F. Levi ◽  
E. Negri ◽  
P. Boyle ◽  
...  
Keyword(s):  
Soft Tissue ◽  
Respiratory Tract ◽  
Cancer Mortality ◽  
Soft Tissue Sarcomas ◽  
Connective And Soft Tissue

Pharmacokinetics and Pharmacodynamics of Linezolid in Obese Patients with Cellulitis

2005 ◽  
Vol 39 (3) ◽  
pp. 427-432 ◽  
Author(s):  
Gary E Stein ◽  
Sharon L Schooley ◽  
Charles A Peloquin ◽  
Vivek Kak ◽  
Daniel H Havlichek ◽  
...  
Keyword(s):  
Soft Tissue ◽  
Inhibitory Activity ◽  
Ideal Body Weight ◽  
Multidrug Resistant ◽  
Obese Patients ◽  
Serum Concentrations ◽  
Serum Samples ◽  
Ideal Body ◽  
The One ◽  
Time Point

BACKGROUND: Linezolid is an oxazolidinone antimicrobial with excellent oral bioavailability and tissue penetration and is active against multidrug-resistant skin/soft tissue pathogens. OBJECTIVE: To study the pharmacokinetics and antibacterial activity of linezolid against selective skin/soft tissue pathogens in obese patients. METHODS: We obtained multiple serum samples from 7 obese patients (>50% over their calculated ideal body weight) receiving oral linezolid 600 mg every 12 hours for treatment of cellulitis. Following a minimum of 3 doses, serum concentrations of linezolid were measured in each subject prior to (trough) and 1 and 6 hours after a dose. These samples were then tested against clinical isolates of methicillin-resistant Staphylococcus aureus (MRSA) (linezolid minimum inhibitory concentrations [MICs] 1.0, 2.0, 4.0 μg/mL) and one strain each of vancomycin-resistant Enterococcus faecium (VRE) (MIC 2.0 μg/mL), Bacteroides fragilis (MIC 2.0 μg/mL), and Peptostreptococcus magnus (MIC 1.0 μg/mL). Serum inhibitory titers (SITs) and bactericidal titers (SBTs) were measured at each time point, and the median activity for these 7 patients was calculated. RESULTS: Mean linezolid serum concentrations were 4.2, 12.3, and 7.2 μg/mL at these respective time points. Median SITs for 12 hours (100% of the dosing interval) were observed against each organism with the exception of the least susceptible strain of MRSA (MIC 4.0 μg/mL); serum inhibitory activity was observed only at the one-hour time point against this isolate. Furthermore, prolonged (⩾6 h) median SBTs were observed against one isolate of MRSA (MIC 1.0 μg/mL) as well as the strain of VRE and P. magnus. CONCLUSIONS: Serum concentrations of oral linezolid in this patient population were diminished compared with those of healthy volunteers, but still provided prolonged serum inhibitory activity against common pathogens associated with skin/soft tissue infections. One treatment concern would be an obese patient receiving oral linezolid who was infected with a less susceptible (MIC ⩾4.0 μg/mL) strain of S. aureus. Bactericidal activity was also observed against selective pathogens.

Sign in / Sign up

Export Citation Format

Share Document